A Randomized, Open-label, Two-period, Crossover Trial to Compare the Pharmacokinetic Profiles Between Albumin-bound Docetaxel and Taxotere in Patients With Advanced Solid Tumors
Latest Information Update: 05 Jun 2023
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 27 Jan 2022 Planned End Date changed from 1 Feb 2022 to 31 Dec 2022.
- 27 Jan 2022 Planned primary completion date changed from 1 Nov 2021 to 31 Oct 2022.
- 27 Jan 2022 Status changed from recruiting to active, no longer recruiting.